...
首页> 外文期刊>The American Journal of Surgery >Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence
【24h】

Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence

机译:治疗原发性和转移性肝脏肿瘤的区域疗法:基于疾病的技术审查和当前证据的批判性评估

获取原文
获取原文并翻译 | 示例
           

摘要

The practice of hepatic surgery has become increasingly complex as additional therapeutic options emerge to treat both primary and metastatic tumors of the liver. Liver-directed therapy options include selective internal radiation therapy (SIRT), stereotactic body radiation therapy, chemoembolization, bland embolization, hepatic artery infusion chemotherapy (HAIC), and ablative techniques such as microwave or radiofrequency ablation. Hepatocellular carcinoma has been treated with many of these therapies for palliation of symptoms, definitive treatment, and as a bridge to transplantation. Intrahepatic cholangiocarcinoma, particularly patients with unresectable disease, have demonstrated clinical responses to both SIRT as well as HAIC. Colorectal liver metastases have been treated with all of these techniques with varying degrees of success depending on the clinical scenario. A detailed understanding of these technologies and the evidence supporting their use is essential for the modern hepatic surgeon to properly sequence therapies and provide salvage options when first-line treatment has failed. This review describes these techniques and their appropriate usage based on the disease of interest and the respective evidence currently available. (C) 2018 Elsevier Inc. All rights reserved.
机译:随着额外的治疗选择来治疗肝脏的主要和转移性肿瘤,肝脏手术的做法变得越来越复杂。肝脏定向治疗选择包括选择性内部放射治疗(SIRT),立体定向体放射治疗,化疗栓塞,平坦栓塞,肝动脉输注化疗(HAIC),以及微波或射频消融等烧蚀技术。肝细胞癌已被许多这些疗法治疗,用于症状,明确的治疗和作为移植桥的桥接。肝内胆管癌,特别是患有不可切除的疾病的患者,对SIRT和HAC均表现出临床反应。根据临床情景,已经通过所有这些技术对所有这些技术进行了处理,这是不同程度的成功。对这些技术的详细了解和支持其使用的证据对现代肝外科医生适用于适当的序列疗法,并在一线治疗失败时提供救助选择。本综述描述了这些技术及其基于兴趣疾病和目前可用的各个证据的适当使用。 (c)2018年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号